We also see other risk managers expanding existing programs – both in terms of higher volumes or new risks such as Cyber or D&O. More companies are evaluating the option of establishing a captive or putting dormant captives back to use. Global Broker Marsh saw more than 100 formations of all types of captives in 2020 and there's no sign the trend is slowing down in 2021.
If you're more aggressive, though, you may want to consider this company due to its game-changing technology. If you're a cautious investor, it's best to wait until Vaxart moves closer to the finish line with at least one candidate. That's why it's best to invest in players like Vaxart only if you can accept this risk. Anything can happen in clinical trials - so there's no guarantee a product and revenue will be right around the corner. And the most advanced is a seasonal flu vaccine candidate in phase 2 studies.Ĭlinical-stage companies always present a certain degree of risk. Vaxart doesn't have any commercialized products, but has six programs in the pipeline. Should you buy Vaxart?ĭoes this mean you should buy Vaxart shares right now? It depends on your investment style. And it means Vaxart still may benefit from sales - in spite of its potentially late arrival. This makes the potential Vaxart product a practical option for use anywhere in the world. (For example, the Moderna and Pfizer vaccines require cold temperatures.)
But here's what's even more important: Healthcare facilities will find it easier to store a room-temperature-stable tablet than an injectable vaccine. As I said earlier, users will be happy to avoid a needle. Otherwise, countries likely will continue to order the vaccines they've already used and know well. But to do so, the company must have an innovative and efficacious candidate. It's very possible a latecomer could carve out market share. And it seems likely that individuals who go for an annual flu shot also will go for a coronavirus jab. I expect countries to buy doses in advance each year. The situation may resemble that of the flu - the virus will come and go in certain areas in an ongoing manner. The coronavirus still will be around, so people still need protection. So a post-pandemic world may be only months away.īut that doesn't necessarily mean bad news for Vaxart or other latecomers. And Pfizer has requested authorization of its vaccine in kids ages five through 11. Merck plans to request authorization of its treatment pill candidate soon.
Scott Gottlieb told CNBC he expects the authorization of a coronavirus treatment pill and vaccines for kids to mark the transition from a pandemic into an endemic phase. Food and Drug Administration (FDA) chief Dr. Moderna, Pfizer, and Johnson & Johnson shared that market. It's clear the company missed out on vaccinating during the pandemic. Now let's look at Vaxart's market prospects.
0 kommentar(er)
